HMG / Menotropins
Evidence: A/DHormone / Fertility
FDA-approved menotropins products exist for specific assisted-reproductive-technology uses. Product composition, indication, route, and labeling are brand-specific and must not be inferred from a catalog entry alone.
Quick Summary
FDA-approved menotropins products exist for specific assisted-reproductive-technology uses. Product composition, indication, route, and labeling are brand-specific and must not be inferred from a catalog entry alone.
HMG usually refers to menotropins, a purified urinary-derived gonadotropin preparation containing FSH and LH activity. It has established fertility-medicine use, while broader or male-use claims require separate evidence and regulatory context.
Mechanism & Research Overview
HMG usually refers to menotropins, a purified urinary-derived gonadotropin preparation containing FSH and LH activity. It has established fertility-medicine use, while broader or male-use claims require separate evidence and regulatory context.
Research Areas Being Studied
Research areas discussed on this page reflect the Hormone / Fertility category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- A randomized assessor-blind trial comparing highly purified menotropin and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer (2012):
- Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cycles (2008):
- Randomized, assessor-blinded trial comparing highly purified human menopausal gonadotropin and recombinant FSH in high responders (2020):
Negative Things to Know
Consideration
Menotropins can cause ovarian hyperstimulation syndrome, including serious pulmonary or vascular complications.Consideration
Multiple gestation and ovarian torsion are recognized treatment risks.Consideration
Catalog “HMG” does not establish the identity, purity, potency, or approval status of a specific product.
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| A randomized assessor-blind trial comparing highly purified menotropin and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer | 2012 | 749 women undergoing controlled ovarian stimulation and single-blastocyst transfer | Findings are specific to the controlled trial design and monitored ART setting. | ||
| Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cycles | 2008 | 986 women randomized in IVF cycles | The study was conducted with specialist ovarian monitoring. | ||
| Randomized, assessor-blinded trial comparing highly purified human menopausal gonadotropin and recombinant FSH in high responders | 2020 | 620 women predicted to be high responders undergoing assisted reproduction | The study does not remove established gonadotropin risks, including ovarian hyperstimulation and multiple gestation. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| MENOPUR (menotropins for injection) U.S. prescribing information | 2018 | FDA-regulated product labeling for women undergoing assisted reproductive technology | Warnings include ovarian hyperstimulation syndrome, pulmonary or vascular complications, ovarian torsion, and multi-fetal gestation. |
Study / Trial Dosing
Dosing entries below are limited to what is directly documented in human studies, clinical trials, or official regulatory sources — never a usage recommendation.
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| A randomized assessor-blind trial comparing highly purified menotropin and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer | 2012 | 749 women undergoing controlled ovarian stimulation and single-blastocyst transfer | Findings are specific to the controlled trial design and monitored ART setting. | ||
| Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cycles | 2008 | 986 women randomized in IVF cycles | The study was conducted with specialist ovarian monitoring. | ||
| MENOPUR (menotropins for injection) U.S. prescribing information | 2018 | FDA-regulated product labeling for women undergoing assisted reproductive technology | Warnings include ovarian hyperstimulation syndrome, pulmonary or vascular complications, ovarian torsion, and multi-fetal gestation. | ||
| Randomized, assessor-blinded trial comparing highly purified human menopausal gonadotropin and recombinant FSH in high responders | 2020 | 620 women predicted to be high responders undergoing assisted reproduction | The study does not remove established gonadotropin risks, including ovarian hyperstimulation and multiple gestation. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-13.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.